Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead to Raise $36M in Private Stock Offering

Premium

Arrowhead Research this week announced that it intends to raise $36 million through a private offering of roughly 14.3 million shares plus 9,900 shares of convertible preferred stock.

The common stock will be priced at $1.83 apiece, and the preferred shares are priced at $1,000 each and are convertible into shares of common stock at a price of $1.83 per share.

Arrowhead said that the offering is expected to close by May 3.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.